What ' s known on the subject? and What does the study add?The desmopressin analogue to antidiuretic vasopressin is an evidence-based therapy but confl icting results are provided regarding the initial dose of oral desmopressin. Previous studies report the use of a combined therapy with desmopressin and oxybutynin to treat desmopressin-resistant monosymptomatic nocturnal enuresis. These studies show promising results, but they suffer from lack of randomization and lack of a placebo-controlled patient group and are of small sample size. In addition to this, no predictive factors of response to the combined therapy have been considered. This study showed no signifi cant difference between either a 120 μ g or a 240 μ g desmopressin initial dose with regard to degree of response. The study is the fi rst randomized, double-blinded, placebo-controlled trial showing the effi cacy of combination therapy with desmopressin plus oxybutynin for monosymptomatic nocturnal enuresis. Furthermore, bladder volume and wall thickness index, nocturnal polyuria and voiding latency were assessed as predictive factors of response to the therapy. OBJECTIVES• To assess the effi cacy of desmopressin plus oxybutynin and compare two starting dosages of desmopressin (120 and 240 μ g) in a randomized, double-blinded, placebocontrolled trial for children with monosymptomatic nocturnal enuresis (MNE) resistant to desmopressin.• The predictive factors of children with MNE responsive to desmopressin and combination therapy were also evaluated. PATIENTS AND METHODS• Our sample included 206 patients aged between 6 and 13 (mean age 10.6 ± 2.9 years), 117 males. All patients were required to have MNE.• The patients were randomly divided into two groups: the fi rst group was given oral melt 120 μ g and the second group 240 μ g, for 2 weeks.• All patients who had experienced failure of treatment with sublingually administered desmopressin alone were given either desmopressin plus 5 mg oxybutynin or desmopressin plus placebo in a randomized, double-blinded trial for 4 weeks.• As predictive factors, bladder volume and wall thickness index, nocturnal polyuria and voiding latency were considered. RESULTS• There was no signifi cant difference between the 120 μ g and 240 μ g patients in terms of response.• The oxybutynin group showed a higher rate of full and partial responses (45% success) compared with the placebo group (17% success), P < 0.01.• The responders to combined oxybutynin and desmopressin had signifi cantly lower bladder volume and wall thickness index than the other patients. CONCLUSIONS• Our fi ndings highlight that anticholinergic agents may play an important role for a subset of children with enuresis who have a restricted bladder capacity and thickened bladder wall.• Ultrasonography-measured bladder variables can provide useful predictive clues for MNE.• Predictive factors can help to differentiate treatment subtypes and guide clinical management in primary nocturnal enuresis. KEYWORDS desmopressin , nocturnal enuresis , oxybutyninStudy Typ...
These findings enabled a close connection between nocturia in adulthood and enuresis in childhood to be hypothesized. Furthermore, this analysis provided evidence of the link between suffering from nocturia, and previously from enuresis, and having children affected by enuresis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.